Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

RANITIDINE HCL

Form:

23 of 23 products shown

20 general benefit · 3 not a benefit

Other products in the same Health Canada class (A02B, A02BA) — coverage varies; not interchangeable

  • Cimetidine (Cimetidine): general benefit, Not a benefit
  • Famotidine (Pepcid): general benefit, Not a benefit
  • Nizatidine (Axid): general benefit
  • Misoprostol (Cytotec): general benefit, Not a benefit
  • Pantoprazole (Tecta): general benefit
  • Rabeprazole (Pariet): general benefit

7 more in the class list below

Mar-Ranitidine · DIN 02443708 · 150mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mar-Ranitidine · DIN 02443708 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2019-01-31 Health Canada: Marketed since 2018-11-09 · brand MAR-RANITIDINE · ATC A02BA02 RANITIDINE · form Tablet · route Oral · ingredients RANITIDINE (RANITIDINE HYDROCHLORIDE) 150 MG · company Marcan pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mar-Ranitidine: Formulary list price $0.1197/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1197 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92844 · Verify on the e-Formulary ↗ (DIN 02443708)

Source record
DIN 02443708: Mar-Ranitidine Raw flags: chronicUseMed=Y, sec3=Y Item: 564000010; group id 697; item number 1722; lccId None; manufacturer id MAR Source form: Tab; strength: 150mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1197; ministry $0.1197 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02443708 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92844
Interchangeable products
Apo-Ranitidine · DIN 00733059 · $0.1197 Co Ranitidine · DIN 02248570 · $0.1197 Jamp-Ranitidine · DIN 02463717 · $0.1197 Mint-Ranitidine · DIN 02526379 · $0.1197 PMS-Ranitidine · DIN 02242453 · $0.1197 Ran-Ranitidine · DIN 02336480 · $0.1197 Sandoz Ranitidine · DIN 02243229 · $0.1197 Teva-Ranitidine · DIN 00828564 · $0.1197 Zantac · DIN 02212331 · not recorded
Shortage status: resolved shortage (ended 2022-01-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02443708
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Ranitidine · DIN 02526379 · 150mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mint-Ranitidine · DIN 02526379 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2023-01-31 Health Canada: Marketed since 2022-10-07 · brand MINT-RANITIDINE · ATC A02BA02 RANITIDINE · form Tablet · route Oral · ingredients RANITIDINE (RANITIDINE HYDROCHLORIDE) 150 MG · company Mint pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mint-Ranitidine: Formulary list price $0.1197/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1197 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101547 · Verify on the e-Formulary ↗ (DIN 02526379)

Source record
DIN 02526379: Mint-Ranitidine Raw flags: chronicUseMed=Y, sec3=Y Item: 564000010; group id 697; item number 1722; lccId None; manufacturer id MIN Source form: Tab; strength: 150mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1197; ministry $0.1197 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02526379 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101547
Interchangeable products
Apo-Ranitidine · DIN 00733059 · $0.1197 Co Ranitidine · DIN 02248570 · $0.1197 Jamp-Ranitidine · DIN 02463717 · $0.1197 Mar-Ranitidine · DIN 02443708 · $0.1197 PMS-Ranitidine · DIN 02242453 · $0.1197 Ran-Ranitidine · DIN 02336480 · $0.1197 Sandoz Ranitidine · DIN 02243229 · $0.1197 Teva-Ranitidine · DIN 00828564 · $0.1197 Zantac · DIN 02212331 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02526379
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mar-Ranitidine · DIN 02443716 · 300mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mar-Ranitidine · DIN 02443716 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2019-01-31 Health Canada: Marketed since 2018-11-09 · brand MAR-RANITIDINE · ATC A02BA02 RANITIDINE · form Tablet · route Oral · ingredients RANITIDINE (RANITIDINE HYDROCHLORIDE) 300 MG · company Marcan pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mar-Ranitidine: Formulary list price $0.2253/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2253 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92845 · Verify on the e-Formulary ↗ (DIN 02443716)

Source record
DIN 02443716: Mar-Ranitidine Raw flags: chronicUseMed=Y, sec3=Y Item: 564000020; group id 697; item number 1723; lccId None; manufacturer id MAR Source form: Tab; strength: 300mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2253; ministry $0.2253 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02443716 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92845
Interchangeable products
Apo-Ranitidine · DIN 00733067 · $0.2253 Co Ranitidine · DIN 02248571 · $0.2253 Jamp-Ranitidine · DIN 02463725 · $0.2253 Mint-Ranitidine · DIN 02526387 · $0.2253 PMS-Ranitidine · DIN 02242454 · $0.2253 Ran-Ranitidine · DIN 02336502 · $0.2253 Sandoz Ranitidine · DIN 02243230 · $0.2253 Teva-Ranitidine · DIN 00828556 · $0.2253 Zantac · DIN 02212358 · not recorded
Shortage status: resolved shortage (ended 2021-12-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02443716
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Ranitidine · DIN 02526387 · 300mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mint-Ranitidine · DIN 02526387 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2023-01-31 Health Canada: Marketed since 2022-10-07 · brand MINT-RANITIDINE · ATC A02BA02 RANITIDINE · form Tablet · route Oral · ingredients RANITIDINE (RANITIDINE HYDROCHLORIDE) 300 MG · company Mint pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mint-Ranitidine: Formulary list price $0.2253/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2253 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101548 · Verify on the e-Formulary ↗ (DIN 02526387)

Source record
DIN 02526387: Mint-Ranitidine Raw flags: chronicUseMed=Y, sec3=Y Item: 564000020; group id 697; item number 1723; lccId None; manufacturer id MIN Source form: Tab; strength: 300mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2253; ministry $0.2253 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02526387 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101548
Interchangeable products
Apo-Ranitidine · DIN 00733067 · $0.2253 Co Ranitidine · DIN 02248571 · $0.2253 Jamp-Ranitidine · DIN 02463725 · $0.2253 Mar-Ranitidine · DIN 02443716 · $0.2253 PMS-Ranitidine · DIN 02242454 · $0.2253 Ran-Ranitidine · DIN 02336502 · $0.2253 Sandoz Ranitidine · DIN 02243230 · $0.2253 Teva-Ranitidine · DIN 00828556 · $0.2253 Zantac · DIN 02212358 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02526387
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Ranitidine · DIN 02280833 · 15mg/mL · Oral Sol

General benefitDormant since 2020-09-14 · checked 2026-09-02 · What does dormant mean?
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Ranitidine · DIN 02280833 Manufacturer: Apotex Inc.; listing date 2007-09-04 Health Canada: Dormant since 2020-09-14 · brand APO-RANITIDINE · ATC A02BA02 RANITIDINE · form Solution · route Oral · ingredients RANITIDINE (RANITIDINE HYDROCHLORIDE) 75 MG/5ML · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Ranitidine: Formulary list price $0.1480/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1480 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76651 · Verify on the e-Formulary ↗ (DIN 02280833)

Source record
DIN 02280833: Apo-Ranitidine Raw flags: sec3=Y Item: 564000038; group id 697; item number 1721; lccId None; manufacturer id APX Source form: Oral Sol; strength: 15mg/mL Recorded listing: General benefit Source prices (unrounded): $0.1480; ministry $0.1480 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02280833 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76651
Interchangeable products
Teva-Ranitidine Solution · DIN 02242940 · $0.1480 Zantac · DIN 02212374 · not recorded
Shortage status: active shortage (reported 2019-09-17, last updated 2019-09-18) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02280833
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2020-09-14 — choose a marketed DIN from the same-category list.

Apo-Ranitidine · DIN 00733059 · 150mg · tablet

General benefitDormant since 2020-09-13 · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Ranitidine · DIN 00733059 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Dormant since 2020-09-13 · brand APO-RANITIDINE TABLET 150MG · ATC A02BA02 RANITIDINE · form Tablet · route Oral · ingredients RANITIDINE (RANITIDINE HYDROCHLORIDE) 150 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Ranitidine: Formulary list price $0.1197/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1197 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=7426 · Verify on the e-Formulary ↗ (DIN 00733059)

Source record
DIN 00733059: Apo-Ranitidine Raw flags: chronicUseMed=Y, sec3=Y Item: 564000010; group id 697; item number 1722; lccId None; manufacturer id APX Source form: Tab; strength: 150mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1197; ministry $0.1197 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00733059 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=7426
Interchangeable products
Co Ranitidine · DIN 02248570 · $0.1197 Jamp-Ranitidine · DIN 02463717 · $0.1197 Mar-Ranitidine · DIN 02443708 · $0.1197 Mint-Ranitidine · DIN 02526379 · $0.1197 PMS-Ranitidine · DIN 02242453 · $0.1197 Ran-Ranitidine · DIN 02336480 · $0.1197 Sandoz Ranitidine · DIN 02243229 · $0.1197 Teva-Ranitidine · DIN 00828564 · $0.1197 Zantac · DIN 02212331 · not recorded
Shortage status: active shortage (reported 2019-09-17, last updated 2019-09-18) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00733059
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2020-09-13 — choose a marketed DIN from the same-category list.

Jamp-Ranitidine · DIN 02463717 · 150mg · tablet

General benefitDormant since 2021-07-29 · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp-Ranitidine · DIN 02463717 Manufacturer: Jamp Pharma Corporation; listing date 2018-12-21 Health Canada: Dormant since 2021-07-29 · brand JAMP-RANITIDINE · ATC A02BA02 RANITIDINE · form Tablet · route Oral · ingredients RANITIDINE (RANITIDINE HYDROCHLORIDE) 150 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp-Ranitidine: Formulary list price $0.1197/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1197 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95181 · Verify on the e-Formulary ↗ (DIN 02463717)

Source record
DIN 02463717: Jamp-Ranitidine Raw flags: chronicUseMed=Y, sec3=Y Item: 564000010; group id 697; item number 1722; lccId None; manufacturer id JPC Source form: Tab; strength: 150mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1197; ministry $0.1197 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02463717 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95181
Interchangeable products
Apo-Ranitidine · DIN 00733059 · $0.1197 Co Ranitidine · DIN 02248570 · $0.1197 Mar-Ranitidine · DIN 02443708 · $0.1197 Mint-Ranitidine · DIN 02526379 · $0.1197 PMS-Ranitidine · DIN 02242453 · $0.1197 Ran-Ranitidine · DIN 02336480 · $0.1197 Sandoz Ranitidine · DIN 02243229 · $0.1197 Teva-Ranitidine · DIN 00828564 · $0.1197 Zantac · DIN 02212331 · not recorded
Shortage status: active shortage (reported 2019-10-07, estimated to end 2022-12-30, last updated 2021-04-07) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02463717
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2021-07-29 — choose a marketed DIN from the same-category list.

Ran-Ranitidine · DIN 02336480 · 150mg · tablet

General benefitDormant since 2021-07-26 · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ran-Ranitidine · DIN 02336480 Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2010-01-05 Health Canada: Dormant since 2021-07-26 · brand RAN-RANITIDINE · ATC A02BA02 RANITIDINE · form Tablet · route Oral · ingredients RANITIDINE (RANITIDINE HYDROCHLORIDE) 150 MG · company Ranbaxy pharmaceuticals canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Ran-Ranitidine: Formulary list price $0.1197/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1197 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82205 · Verify on the e-Formulary ↗ (DIN 02336480)

Source record
DIN 02336480: Ran-Ranitidine Raw flags: chronicUseMed=Y, sec3=Y Item: 564000010; group id 697; item number 1722; lccId None; manufacturer id RAN Source form: Tab; strength: 150mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1197; ministry $0.1197 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02336480 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82205
Interchangeable products
Apo-Ranitidine · DIN 00733059 · $0.1197 Co Ranitidine · DIN 02248570 · $0.1197 Jamp-Ranitidine · DIN 02463717 · $0.1197 Mar-Ranitidine · DIN 02443708 · $0.1197 Mint-Ranitidine · DIN 02526379 · $0.1197 PMS-Ranitidine · DIN 02242453 · $0.1197 Sandoz Ranitidine · DIN 02243229 · $0.1197 Teva-Ranitidine · DIN 00828564 · $0.1197 Zantac · DIN 02212331 · not recorded
Shortage status: resolved shortage (ended 2020-06-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02336480
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2021-07-26 — choose a marketed DIN from the same-category list.

Apo-Ranitidine · DIN 00733067 · 300mg · tablet

General benefitDormant since 2020-09-13 · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Ranitidine · DIN 00733067 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Dormant since 2020-09-13 · brand APO-RANITIDINE TABLET 300MG · ATC A02BA02 RANITIDINE · form Tablet · route Oral · ingredients RANITIDINE (RANITIDINE HYDROCHLORIDE) 300 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Ranitidine: Formulary list price $0.2253/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2253 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=7427 · Verify on the e-Formulary ↗ (DIN 00733067)

Source record
DIN 00733067: Apo-Ranitidine Raw flags: chronicUseMed=Y, sec3=Y Item: 564000020; group id 697; item number 1723; lccId None; manufacturer id APX Source form: Tab; strength: 300mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2253; ministry $0.2253 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00733067 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=7427
Interchangeable products
Co Ranitidine · DIN 02248571 · $0.2253 Jamp-Ranitidine · DIN 02463725 · $0.2253 Mar-Ranitidine · DIN 02443716 · $0.2253 Mint-Ranitidine · DIN 02526387 · $0.2253 PMS-Ranitidine · DIN 02242454 · $0.2253 Ran-Ranitidine · DIN 02336502 · $0.2253 Sandoz Ranitidine · DIN 02243230 · $0.2253 Teva-Ranitidine · DIN 00828556 · $0.2253 Zantac · DIN 02212358 · not recorded
Shortage status: active shortage (reported 2019-09-17, last updated 2019-09-18) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00733067
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2020-09-13 — choose a marketed DIN from the same-category list.

Jamp-Ranitidine · DIN 02463725 · 300mg · tablet

General benefitDormant since 2021-07-29 · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp-Ranitidine · DIN 02463725 Manufacturer: Jamp Pharma Corporation; listing date 2018-12-21 Health Canada: Dormant since 2021-07-29 · brand JAMP-RANITIDINE · ATC A02BA02 RANITIDINE · form Tablet · route Oral · ingredients RANITIDINE (RANITIDINE HYDROCHLORIDE) 300 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp-Ranitidine: Formulary list price $0.2253/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2253 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95182 · Verify on the e-Formulary ↗ (DIN 02463725)

Source record
DIN 02463725: Jamp-Ranitidine Raw flags: chronicUseMed=Y, sec3=Y Item: 564000020; group id 697; item number 1723; lccId None; manufacturer id JPC Source form: Tab; strength: 300mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2253; ministry $0.2253 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02463725 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95182
Interchangeable products
Apo-Ranitidine · DIN 00733067 · $0.2253 Co Ranitidine · DIN 02248571 · $0.2253 Mar-Ranitidine · DIN 02443716 · $0.2253 Mint-Ranitidine · DIN 02526387 · $0.2253 PMS-Ranitidine · DIN 02242454 · $0.2253 Ran-Ranitidine · DIN 02336502 · $0.2253 Sandoz Ranitidine · DIN 02243230 · $0.2253 Teva-Ranitidine · DIN 00828556 · $0.2253 Zantac · DIN 02212358 · not recorded
Shortage status: active shortage (reported 2019-10-07, estimated to end 2022-12-30, last updated 2021-04-07) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02463725
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2021-07-29 — choose a marketed DIN from the same-category list.

Ran-Ranitidine · DIN 02336502 · 300mg · tablet

General benefitDormant since 2021-07-26 · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ran-Ranitidine · DIN 02336502 Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2010-01-05 Health Canada: Dormant since 2021-07-26 · brand RAN-RANITIDINE · ATC A02BA02 RANITIDINE · form Tablet · route Oral · ingredients RANITIDINE (RANITIDINE HYDROCHLORIDE) 300 MG · company Ranbaxy pharmaceuticals canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Ran-Ranitidine: Formulary list price $0.2253/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2253 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82207 · Verify on the e-Formulary ↗ (DIN 02336502)

Source record
DIN 02336502: Ran-Ranitidine Raw flags: chronicUseMed=Y, sec3=Y Item: 564000020; group id 697; item number 1723; lccId None; manufacturer id RAN Source form: Tab; strength: 300mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2253; ministry $0.2253 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02336502 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82207
Interchangeable products
Apo-Ranitidine · DIN 00733067 · $0.2253 Co Ranitidine · DIN 02248571 · $0.2253 Jamp-Ranitidine · DIN 02463725 · $0.2253 Mar-Ranitidine · DIN 02443716 · $0.2253 Mint-Ranitidine · DIN 02526387 · $0.2253 PMS-Ranitidine · DIN 02242454 · $0.2253 Sandoz Ranitidine · DIN 02243230 · $0.2253 Teva-Ranitidine · DIN 00828556 · $0.2253 Zantac · DIN 02212358 · not recorded
Shortage status: resolved shortage (ended 2020-06-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02336502
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2021-07-26 — choose a marketed DIN from the same-category list.

Teva-Ranitidine Solution · DIN 02242940 · 15mg/mL · Oral Sol

General benefit; Health Canada lists this DIN as Cancelled post market since 2020-06-10 — choose a marketed DIN from the same-category list.Discontinued 2020-06-10 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2020-06-10 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2020-06-10 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Ranitidine Solution · DIN 02242940 Manufacturer: Teva Canada Limited; listing date 2004-12-21 Health Canada: Cancelled post market since 2020-06-10 · brand TEVA-RANITIDINE SOLUTION · ATC A02BA02 RANITIDINE · form Solution · route Oral · ingredients RANITIDINE (RANITIDINE HYDROCHLORIDE) 75 MG/5ML · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Ranitidine Solution: Formulary list price $0.1480/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1480 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66779 · Verify on the e-Formulary ↗ (DIN 02242940)

Source record
DIN 02242940: Teva-Ranitidine Solution Raw flags: sec3=Y Item: 564000038; group id 697; item number 1721; lccId None; manufacturer id TEV Source form: Oral Sol; strength: 15mg/mL Recorded listing: General benefit Source prices (unrounded): $0.1480; ministry $0.1480 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02242940 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66779
Interchangeable products
Apo-Ranitidine · DIN 02280833 · $0.1480 Zantac · DIN 02212374 · not recorded
Shortage status: discontinued (2018-10-30, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02242940
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2020-06-10 — choose a marketed DIN from the same-category list.

Co Ranitidine · DIN 02248570 · 150mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2020-08-17 — choose a marketed DIN from the same-category list.Discontinued 2020-08-17 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2020-08-17 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2020-08-17 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Co Ranitidine · DIN 02248570 Manufacturer: Cobalt Pharmaceuticals Company; listing date 2004-07-20 Health Canada: Cancelled post market since 2020-08-17 · brand ACT RANITIDINE · ATC A02BA02 RANITIDINE · form Tablet · route Oral · ingredients RANITIDINE (RANITIDINE HYDROCHLORIDE) 150 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Co Ranitidine: Formulary list price $0.1197/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1197 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72925 · Verify on the e-Formulary ↗ (DIN 02248570)

Source record
DIN 02248570: Co Ranitidine Raw flags: chronicUseMed=Y, sec3=Y Item: 564000010; group id 697; item number 1722; lccId None; manufacturer id COB Source form: Tab; strength: 150mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1197; ministry $0.1197 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02248570 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72925
Interchangeable products
Apo-Ranitidine · DIN 00733059 · $0.1197 Jamp-Ranitidine · DIN 02463717 · $0.1197 Mar-Ranitidine · DIN 02443708 · $0.1197 Mint-Ranitidine · DIN 02526379 · $0.1197 PMS-Ranitidine · DIN 02242453 · $0.1197 Ran-Ranitidine · DIN 02336480 · $0.1197 Sandoz Ranitidine · DIN 02243229 · $0.1197 Teva-Ranitidine · DIN 00828564 · $0.1197 Zantac · DIN 02212331 · not recorded
Shortage status: resolved shortage (ended 2020-05-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02248570
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2020-08-17 — choose a marketed DIN from the same-category list.

PMS-Ranitidine · DIN 02242453 · 150mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2025-07-04 — choose a marketed DIN from the same-category list.Discontinued 2025-07-04 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2025-07-04 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2025-07-04 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Ranitidine · DIN 02242453 Manufacturer: Pharmascience Inc.; listing date 2001-03-07 Health Canada: Cancelled post market since 2025-07-04 · brand PMS-RANITIDINE 150 MG · ATC A02BA02 RANITIDINE · form Tablet · route Oral · ingredients RANITIDINE (RANITIDINE HYDROCHLORIDE) 150 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Ranitidine: Formulary list price $0.1197/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1197 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66172 · Verify on the e-Formulary ↗ (DIN 02242453)

Source record
DIN 02242453: PMS-Ranitidine Raw flags: chronicUseMed=Y, sec3=Y Item: 564000010; group id 697; item number 1722; lccId None; manufacturer id PMS Source form: Tab; strength: 150mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1197; ministry $0.1197 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02242453 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66172
Interchangeable products
Apo-Ranitidine · DIN 00733059 · $0.1197 Co Ranitidine · DIN 02248570 · $0.1197 Jamp-Ranitidine · DIN 02463717 · $0.1197 Mar-Ranitidine · DIN 02443708 · $0.1197 Mint-Ranitidine · DIN 02526379 · $0.1197 Ran-Ranitidine · DIN 02336480 · $0.1197 Sandoz Ranitidine · DIN 02243229 · $0.1197 Teva-Ranitidine · DIN 00828564 · $0.1197 Zantac · DIN 02212331 · not recorded
Shortage status: active shortage (reported 2019-10-23, last updated 2022-12-06) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02242453
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2025-07-04 — choose a marketed DIN from the same-category list.

Sandoz Ranitidine · DIN 02243229 · 150mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2021-03-01 — choose a marketed DIN from the same-category list.Discontinued 2021-03-01 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2021-03-01 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2021-03-01 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Sandoz Ranitidine · DIN 02243229 Manufacturer: Sandoz Canada Inc.; listing date 2001-10-11 Health Canada: Cancelled post market since 2021-03-01 · brand SANDOZ RANITIDINE · ATC A02BA02 RANITIDINE · form Tablet · route Oral · ingredients RANITIDINE (RANITIDINE HYDROCHLORIDE) 150 MG · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Sandoz Ranitidine: Formulary list price $0.1197/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1197 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67115 · Verify on the e-Formulary ↗ (DIN 02243229)

Source record
DIN 02243229: Sandoz Ranitidine Raw flags: chronicUseMed=Y, sec3=Y Item: 564000010; group id 697; item number 1722; lccId None; manufacturer id SDZ Source form: Tab; strength: 150mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1197; ministry $0.1197 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02243229 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67115
Interchangeable products
Apo-Ranitidine · DIN 00733059 · $0.1197 Co Ranitidine · DIN 02248570 · $0.1197 Jamp-Ranitidine · DIN 02463717 · $0.1197 Mar-Ranitidine · DIN 02443708 · $0.1197 Mint-Ranitidine · DIN 02526379 · $0.1197 PMS-Ranitidine · DIN 02242453 · $0.1197 Ran-Ranitidine · DIN 02336480 · $0.1197 Teva-Ranitidine · DIN 00828564 · $0.1197 Zantac · DIN 02212331 · not recorded
Shortage status: resolved shortage (ended 2021-03-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02243229
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2021-03-01 — choose a marketed DIN from the same-category list.

Teva-Ranitidine · DIN 00828564 · 150mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2018-06-22 — choose a marketed DIN from the same-category list.Discontinued 2018-06-22 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2018-06-22 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2018-06-22 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Ranitidine · DIN 00828564 Manufacturer: Teva Canada Limited; listing date 1996-10-01 Health Canada: Cancelled post market since 2018-06-22 · brand TEVA-RANITIDINE · ATC A02BA02 RANITIDINE · form Tablet · route Oral · ingredients RANITIDINE (RANITIDINE HYDROCHLORIDE) 150 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Ranitidine: Formulary list price $0.1197/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1197 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9891 · Verify on the e-Formulary ↗ (DIN 00828564)

Source record
DIN 00828564: Teva-Ranitidine Raw flags: chronicUseMed=Y, sec3=Y Item: 564000010; group id 697; item number 1722; lccId None; manufacturer id TEV Source form: Tab; strength: 150mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1197; ministry $0.1197 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00828564 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9891
Interchangeable products
Apo-Ranitidine · DIN 00733059 · $0.1197 Co Ranitidine · DIN 02248570 · $0.1197 Jamp-Ranitidine · DIN 02463717 · $0.1197 Mar-Ranitidine · DIN 02443708 · $0.1197 Mint-Ranitidine · DIN 02526379 · $0.1197 PMS-Ranitidine · DIN 02242453 · $0.1197 Ran-Ranitidine · DIN 02336480 · $0.1197 Sandoz Ranitidine · DIN 02243229 · $0.1197 Zantac · DIN 02212331 · not recorded
Shortage status: discontinued (2017-04-07, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00828564
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2018-06-22 — choose a marketed DIN from the same-category list.

Co Ranitidine · DIN 02248571 · 300mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2020-08-17 — choose a marketed DIN from the same-category list.Discontinued 2020-08-17 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2020-08-17 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2020-08-17 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Co Ranitidine · DIN 02248571 Manufacturer: Cobalt Pharmaceuticals Company; listing date 2004-07-20 Health Canada: Cancelled post market since 2020-08-17 · brand ACT RANITIDINE · ATC A02BA02 RANITIDINE · form Tablet · route Oral · ingredients RANITIDINE (RANITIDINE HYDROCHLORIDE) 300 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Co Ranitidine: Formulary list price $0.2253/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2253 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72926 · Verify on the e-Formulary ↗ (DIN 02248571)

Source record
DIN 02248571: Co Ranitidine Raw flags: chronicUseMed=Y, sec3=Y Item: 564000020; group id 697; item number 1723; lccId None; manufacturer id COB Source form: Tab; strength: 300mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2253; ministry $0.2253 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02248571 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72926
Interchangeable products
Apo-Ranitidine · DIN 00733067 · $0.2253 Jamp-Ranitidine · DIN 02463725 · $0.2253 Mar-Ranitidine · DIN 02443716 · $0.2253 Mint-Ranitidine · DIN 02526387 · $0.2253 PMS-Ranitidine · DIN 02242454 · $0.2253 Ran-Ranitidine · DIN 02336502 · $0.2253 Sandoz Ranitidine · DIN 02243230 · $0.2253 Teva-Ranitidine · DIN 00828556 · $0.2253 Zantac · DIN 02212358 · not recorded
Shortage status: resolved shortage (ended 2020-05-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02248571
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2020-08-17 — choose a marketed DIN from the same-category list.

PMS-Ranitidine · DIN 02242454 · 300mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2025-07-04 — choose a marketed DIN from the same-category list.Discontinued 2025-07-04 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2025-07-04 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2025-07-04 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Ranitidine · DIN 02242454 Manufacturer: Pharmascience Inc.; listing date 2001-03-07 Health Canada: Cancelled post market since 2025-07-04 · brand PMS-RANITIDINE 300 MG · ATC A02BA02 RANITIDINE · form Tablet · route Oral · ingredients RANITIDINE (RANITIDINE HYDROCHLORIDE) 300 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Ranitidine: Formulary list price $0.2253/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2253 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66173 · Verify on the e-Formulary ↗ (DIN 02242454)

Source record
DIN 02242454: PMS-Ranitidine Raw flags: chronicUseMed=Y, sec3=Y Item: 564000020; group id 697; item number 1723; lccId None; manufacturer id PMS Source form: Tab; strength: 300mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2253; ministry $0.2253 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02242454 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66173
Interchangeable products
Apo-Ranitidine · DIN 00733067 · $0.2253 Co Ranitidine · DIN 02248571 · $0.2253 Jamp-Ranitidine · DIN 02463725 · $0.2253 Mar-Ranitidine · DIN 02443716 · $0.2253 Mint-Ranitidine · DIN 02526387 · $0.2253 Ran-Ranitidine · DIN 02336502 · $0.2253 Sandoz Ranitidine · DIN 02243230 · $0.2253 Teva-Ranitidine · DIN 00828556 · $0.2253 Zantac · DIN 02212358 · not recorded
Shortage status: active shortage (reported 2019-10-23, last updated 2023-05-15) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02242454
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2025-07-04 — choose a marketed DIN from the same-category list.

Sandoz Ranitidine · DIN 02243230 · 300mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2021-03-01 — choose a marketed DIN from the same-category list.Discontinued 2021-03-01 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2021-03-01 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2021-03-01 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Sandoz Ranitidine · DIN 02243230 Manufacturer: Sandoz Canada Inc.; listing date 2001-10-11 Health Canada: Cancelled post market since 2021-03-01 · brand SANDOZ RANITIDINE · ATC A02BA02 RANITIDINE · form Tablet · route Oral · ingredients RANITIDINE (RANITIDINE HYDROCHLORIDE) 300 MG · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Sandoz Ranitidine: Formulary list price $0.2253/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2253 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67116 · Verify on the e-Formulary ↗ (DIN 02243230)

Source record
DIN 02243230: Sandoz Ranitidine Raw flags: chronicUseMed=Y, sec3=Y Item: 564000020; group id 697; item number 1723; lccId None; manufacturer id SDZ Source form: Tab; strength: 300mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2253; ministry $0.2253 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02243230 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67116
Interchangeable products
Apo-Ranitidine · DIN 00733067 · $0.2253 Co Ranitidine · DIN 02248571 · $0.2253 Jamp-Ranitidine · DIN 02463725 · $0.2253 Mar-Ranitidine · DIN 02443716 · $0.2253 Mint-Ranitidine · DIN 02526387 · $0.2253 PMS-Ranitidine · DIN 02242454 · $0.2253 Ran-Ranitidine · DIN 02336502 · $0.2253 Teva-Ranitidine · DIN 00828556 · $0.2253 Zantac · DIN 02212358 · not recorded
Shortage status: resolved shortage (ended 2021-03-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02243230
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2021-03-01 — choose a marketed DIN from the same-category list.

Teva-Ranitidine · DIN 00828556 · 300mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2018-06-22 — choose a marketed DIN from the same-category list.Discontinued 2018-06-22 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2018-06-22 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2018-06-22 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Ranitidine · DIN 00828556 Manufacturer: Teva Canada Limited; listing date 1996-10-01 Health Canada: Cancelled post market since 2018-06-22 · brand TEVA-RANITIDINE · ATC A02BA02 RANITIDINE · form Tablet · route Oral · ingredients RANITIDINE (RANITIDINE HYDROCHLORIDE) 300 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Ranitidine: Formulary list price $0.2253/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2253 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9890 · Verify on the e-Formulary ↗ (DIN 00828556)

Source record
DIN 00828556: Teva-Ranitidine Raw flags: chronicUseMed=Y, sec3=Y Item: 564000020; group id 697; item number 1723; lccId None; manufacturer id TEV Source form: Tab; strength: 300mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.2253; ministry $0.2253 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00828556 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9890
Interchangeable products
Apo-Ranitidine · DIN 00733067 · $0.2253 Co Ranitidine · DIN 02248571 · $0.2253 Jamp-Ranitidine · DIN 02463725 · $0.2253 Mar-Ranitidine · DIN 02443716 · $0.2253 Mint-Ranitidine · DIN 02526387 · $0.2253 PMS-Ranitidine · DIN 02242454 · $0.2253 Ran-Ranitidine · DIN 02336502 · $0.2253 Sandoz Ranitidine · DIN 02243230 · $0.2253 Zantac · DIN 02212358 · not recorded
Shortage status: discontinued (2017-04-07, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00828556
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2018-06-22 — choose a marketed DIN from the same-category list.

Zantac · DIN 02212374 · 15mg/mL · Oral Sol

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2012-02-29 — choose a marketed DIN from the same-category list.Discontinued 2012-02-29 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2012-02-29 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2012-02-29 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Zantac · DIN 02212374 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 1997-01-20 Health Canada: Cancelled post market since 2012-02-29 · brand ZANTAC · ATC A02BA02 RANITIDINE · form Solution · route Oral · ingredients RANITIDINE (RANITIDINE HYDROCHLORIDE) 15 MG/ML · company Glaxosmithkline inc · schedule Prescription
Check this DIN again · Health Canada product record

Zantac: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43095 · Verify on the e-Formulary ↗ (DIN 02212374)

Source record
DIN 02212374: Zantac Raw flags: notABenefit=Y, sec3=Y Item: 564000038; group id 697; item number 1721; lccId None; manufacturer id GSK Source form: Oral Sol; strength: 15mg/mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02212374 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43095
Interchangeable products
Apo-Ranitidine · DIN 02280833 · $0.1480 Teva-Ranitidine Solution · DIN 02242940 · $0.1480
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02212374
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2012-02-29 — choose a marketed DIN from the same-category list.

Zantac · DIN 02212331 · 150mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-09-14 — choose a marketed DIN from the same-category list.Discontinued 2017-09-14 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-09-14 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2017-09-14 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Zantac · DIN 02212331 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 1997-07-12 Health Canada: Cancelled post market since 2017-09-14 · brand ZANTAC · ATC A02BA02 RANITIDINE · form Tablet · route Oral · ingredients RANITIDINE (RANITIDINE HYDROCHLORIDE) 150 MG · company Glaxosmithkline inc · schedule Prescription
Check this DIN again · Health Canada product record

Zantac: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43092 · Verify on the e-Formulary ↗ (DIN 02212331)

Source record
DIN 02212331: Zantac Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 564000010; group id 697; item number 1722; lccId None; manufacturer id GSK Source form: Tab; strength: 150mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02212331 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43092
Interchangeable products
Apo-Ranitidine · DIN 00733059 · $0.1197 Co Ranitidine · DIN 02248570 · $0.1197 Jamp-Ranitidine · DIN 02463717 · $0.1197 Mar-Ranitidine · DIN 02443708 · $0.1197 Mint-Ranitidine · DIN 02526379 · $0.1197 PMS-Ranitidine · DIN 02242453 · $0.1197 Ran-Ranitidine · DIN 02336480 · $0.1197 Sandoz Ranitidine · DIN 02243229 · $0.1197 Teva-Ranitidine · DIN 00828564 · $0.1197
Shortage status: resolved shortage (ended 2017-09-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02212331
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2017-09-14 — choose a marketed DIN from the same-category list.

Zantac · DIN 02212358 · 300mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-09-14 — choose a marketed DIN from the same-category list.Discontinued 2017-09-14 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2017-09-14 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2017-09-14 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Zantac · DIN 02212358 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 1998-03-17 Health Canada: Cancelled post market since 2017-09-14 · brand ZANTAC · ATC A02BA02 RANITIDINE · form Tablet · route Oral · ingredients RANITIDINE (RANITIDINE HYDROCHLORIDE) 300 MG · company Glaxosmithkline inc · schedule Prescription
Check this DIN again · Health Canada product record

Zantac: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43093 · Verify on the e-Formulary ↗ (DIN 02212358)

Source record
DIN 02212358: Zantac Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 564000020; group id 697; item number 1723; lccId None; manufacturer id GSK Source form: Tab; strength: 300mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02212358 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43093
Interchangeable products
Apo-Ranitidine · DIN 00733067 · $0.2253 Co Ranitidine · DIN 02248571 · $0.2253 Jamp-Ranitidine · DIN 02463725 · $0.2253 Mar-Ranitidine · DIN 02443716 · $0.2253 Mint-Ranitidine · DIN 02526387 · $0.2253 PMS-Ranitidine · DIN 02242454 · $0.2253 Ran-Ranitidine · DIN 02336502 · $0.2253 Sandoz Ranitidine · DIN 02243230 · $0.2253 Teva-Ranitidine · DIN 00828556 · $0.2253
Shortage status: resolved shortage (ended 2017-09-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02212358
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2017-09-14 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (56:40 Miscellaneous G.I. Drugs) and how they are covered

Matched class: 56:40 Miscellaneous G.I. Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BUDESONIDE, MESALAZINE, NIZATIDINE, OLSALAZINE SODIUM, PANTOPRAZOLE MAGNESIUM, RABEPRAZOLE SODIUM, SUCRALFATE Some products covered without a code (check the product listing): 5-AMINOSALICYLIC ACID, CIMETIDINE, DOMPERIDONE MALEATE, FAMOTIDINE, LACTULOSE, METOCLOPRAMIDE HCL, MISOPROSTOL 56:40 Miscellaneous G.I. Drugs

CIMETIDINE

· 10 products · General benefit (5), Listed, not a benefit (5) · strengths: 200mg, 300mg, 400mg, 600mg, 800mg · Tab

FAMOTIDINE

· 16 products · Listed, not a benefit (2), General benefit (14) · strengths: 20mg, 40mg · Tab

NIZATIDINE

· 2 products · General benefit · strengths: 150mg, 300mg · Cap

MISOPROSTOL

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 100mcg, 200mcg · Tab

PANTOPRAZOLE MAGNESIUM

· 6 products · General benefit · strengths: 40mg · Ent Coated Tab

RABEPRAZOLE SODIUM

· 16 products · General benefit · strengths: 10mg, 20mg · Tab

SUCRALFATE

· 4 products · General benefit · strengths: 1g/5mL, 1g · Oral Susp, Tab

LANSOPRAZOLE

· 16 products · Limited Use, codes 293, 295, 297, 401, 402 · strengths: 15mg, 30mg · DR Cap

LANSOPRAZOLE & CLARITHROMYCIN & AMOXICILLIN

· 2 products · Listed, not a benefit (1), Limited Use, codes 306, 307 (1) · strengths: 30mg & 500mg & 500mg · Tab/Cap Pk

OMEPRAZOLE

· 19 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (2), Limited Use, codes 293, 297, 401, 402 (13) · strengths: 10mg, 20mg · DR Cap

PANTOPRAZOLE SODIUM

· 30 products · Off-Formulary Interchangeable, not an ODB benefit (10), Limited Use, codes 293, 295, 297, 401, 402 (20) · strengths: 20mg, 40mg · Ent Tab

DEXLANSOPRAZOLE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 30mg, 60mg · DR Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 56:40 and 10 more
Full class listing Related classes: 56:04 Antacids and Adsorbents, 56:08 Antidiarrhea Agents, 56:12 Cathartics, 56:16 Digestants, 56:22 Antiemetics and Antinauseants Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE MAR-RANITIDINE (ranitidine hydrochloride) Tablets are indicated for the treatment of duodenal ulcer, benign gastric ulcer, reflux esophagitis, post-operative peptic ulcer, Zollinger-Ellison Syndrome, and other conditions where reduction of gastric secretion and acid output is desirable. These include the following:  The treatment of nonsteroidal anti-inflammatory drug (NSAID) – induced lesions, both ulcers and erosions, and their gastrointestinal (GI) symptoms and the prevention of their recurrence;  The prophylaxis of GI hemorrhage from stress ulceration in seriously ill patients;  The prophylaxis of recurrent hemorrhage from bleeding ulcers;  The prevention of Acid Aspiration Syndrome from general anaesthesia in patients considered to be at risk for this, including obstetrical patients in labour, and obese patients. In addition, MAR-RANITIDINE is indicated for the prophylaxis and maintenance treatment of duodenal or benign gastric ulcer in patients with a history of recurrent ulceration. https://pdf.hres.ca/dpd_pm/00034672.PDF PM date: not printed or not captured Source product: MAR-RANITIDINE; DIN 02443708; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Apo-Ranitidine · DIN 02280833 Shortage status: active shortage (reported 2019-09-17, last updated 2019-09-18) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02280833

Check this DIN again

Apo-Ranitidine · DIN 00733059 Shortage status: active shortage (reported 2019-09-17, last updated 2019-09-18) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00733059

Check this DIN again

Jamp-Ranitidine · DIN 02463717 Shortage status: active shortage (reported 2019-10-07, estimated to end 2022-12-30, last updated 2021-04-07) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02463717

Check this DIN again

Apo-Ranitidine · DIN 00733067 Shortage status: active shortage (reported 2019-09-17, last updated 2019-09-18) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00733067

Check this DIN again

Jamp-Ranitidine · DIN 02463725 Shortage status: active shortage (reported 2019-10-07, estimated to end 2022-12-30, last updated 2021-04-07) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02463725

Check this DIN again

Teva-Ranitidine Solution · DIN 02242940 Shortage status: discontinued (2018-10-30, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02242940

Check this DIN again

PMS-Ranitidine · DIN 02242453 Shortage status: active shortage (reported 2019-10-23, last updated 2022-12-06) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02242453

Check this DIN again

Teva-Ranitidine · DIN 00828564 Shortage status: discontinued (2017-04-07, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00828564

Check this DIN again

PMS-Ranitidine · DIN 02242454 Shortage status: active shortage (reported 2019-10-23, last updated 2023-05-15) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02242454

Check this DIN again

Teva-Ranitidine · DIN 00828556 Shortage status: discontinued (2017-04-07, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00828556

Check this DIN again
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)

Other review policies

For Zantac: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026